These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11170502)

  • 1. Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.
    Gorlewska K; Mazerska Z; Sowiński P; Konopa J
    Chem Res Toxicol; 2001 Jan; 14(1):1-10. PubMed ID: 11170502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mode of action of cytotoxic and antitumor 1-nitroacridines. II. In vivo enzyme-mediated covalent binding of a 1-nitroacridine derivative, Ledakrin or Nitracrine, with dna and other macromolecules of mammalian or bacterial cells.
    Pawlak JW; Pawlak K; Konopa J
    Chem Biol Interact; 1983 Feb; 43(2):151-73. PubMed ID: 6402314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells.
    Wiśniewska A; Niemira M; Jagiełło K; Potęga A; Swist M; Henderson C; Skwarska A; Augustin E; Konopa J; Mazerska Z
    Biochem Pharmacol; 2012 Jul; 84(1):30-42. PubMed ID: 22484277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 32P-post-labeling analysis of DNA adduct formation by antitumor drug nitracrine (Ledakrin) and other nitroacridines in different biological systems.
    Bartoszek A; Konopa J
    Biochem Pharmacol; 1989 Apr; 38(8):1301-12. PubMed ID: 2706021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
    Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
    Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311.
    Mazerska Z; Sowiński P; Konopa J
    Biochem Pharmacol; 2003 Nov; 66(9):1727-36. PubMed ID: 14563483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
    Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
    J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complexes of nitracrine with DNA. Stoichiometry of binding.
    Szmigiero L; Gniazdowski M
    Arzneimittelforschung; 1981; 31(11):1875-7. PubMed ID: 7198467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by antitumor 1-nitroacridines.
    Bartoszek A; Dackiewicz P; Konopa J
    Chem Biol Interact; 1997 Feb; 103(2):131-9. PubMed ID: 9055871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of substituents on the metabolism of nitracrine in rat.
    Robertson IG; Bland TJ; Palmer BD
    Xenobiotica; 1996 May; 26(5):559-69. PubMed ID: 8736066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro DNA crosslinking by Ledakrin, an antitumor derivative of 1-nitro-9-aminoacridine.
    Bartoszek A; Dackiewicz P; Składanowski A; Konopa J
    Chem Biol Interact; 1997 Feb; 103(2):141-51. PubMed ID: 9055872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of chromium(VI) to chromium(V) by rat liver cytosolic and microsomal fractions: is DT-diaphorase involved?
    Aiyar J; De Flora S; Wetterhahn KE
    Carcinogenesis; 1992 Jul; 13(7):1159-66. PubMed ID: 1379126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy.
    Stiborová M; Frei E; Sopko B; Wiessler M; Schmeiser HH
    Carcinogenesis; 2002 Apr; 23(4):617-25. PubMed ID: 11960915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1H and 13C NMR characteristics of the anticancerous derivative of acridine: Ledakrin C-283 (nitracrine).
    Wieczorkiewicz T; Lubas B; Siatecki Z; Kozłowski H
    Acta Biochim Pol; 1983; 30(1):71-82. PubMed ID: 6868905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intercalation model for DNA-cross linking in a 1-nitro-9-aminoacridine derivative, an analog of the antitumor agent "ledakrin" (nitracrine).
    Stallings WC; Glusker JP; Carrell HL; Bogucka-Ledóchowska M; Ledóchowski A; Stezowski JJ
    J Biomol Struct Dyn; 1984 Dec; 2(3):511-24. PubMed ID: 6400911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
    Walton MI; Workman P
    Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
    Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
    Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of inhibition of DNA replication in HeLa S3 cells by the antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines.
    Woynarowski JM; Bartoszek A
    Biochim Biophys Acta; 1985 Jun; 825(2):244-53. PubMed ID: 4005263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of novel stable deoxyguanosine and deoxyadenosine adducts of benzo[a]pyrene-7,8-quinone from reactions at physiological pH.
    Balu N; Padgett WT; Lambert GR; Swank AE; Richard AM; Nesnow S
    Chem Res Toxicol; 2004 Jun; 17(6):827-38. PubMed ID: 15206904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.